Neratinib with the Aurora inhibitor GSK-1070916 and neratinib with a taxane were further tested in three sets of cell lines with amplified or non-amplified MYC, from breast, colon and lung cancers (Figs 9, 10 and S4, S5 Figs). This evidence concerns the gene MYC and lung carcinoma.